Management Team



 

W.K. (Bill) Rader

CEO

Mr. Rader is a serial entrepreneur who sold his first company at age 18. To date he has launched five ventures and orchestrated multiple M&A's. Mr. Rader founded Efferent Labs, Inc. in 2011 with a passion derived from his personal experience. He created Efferent on the shoulders of a company he founded in 1998 and successfully exited in 2015, Raland Technologies (now Raland Compliance Partners). Mr. Rader grew Raland from a one-man startup to an Inc. 500|5000 company with a global footprint and 4 divisions. While leading Raland, he established strategic office locations and provided services to clients including Fortune 500 pharmaceutical, biotech and medical device companies throughout the United States, Europe and Asia. His efforts enabled Raland to become one of the most highly respected and sought after providers within the Life Science industry.

Mr. Rader started his career in the engineering sector of the U.S. Navy as a Nuclear Engineering Reactor Controls member of the Submarine Fleet. He holds a Bachelor of Science in Electrical Engineering, is a member of Harvard Business School, Business Innovations in Global Healthcare class of 2015, and a graduate of the University at Buffalo, School of Management. Mr. Rader is a NYBio Fellow, and a member of many industry organizations including ISPE, PDA, IEEE, MedTech, Tech Council/MDBio, and ISA.

Spencer Z. Rosero, MD

Chief Medical Officer

Dr. Rosero serves as the Chief Medical Officer of Efferent Labs, Inc., working with the Scientific Advisors and directing discovery activity.

Dr. Rosero is Professor of Medicine at the University of Rochester School of Medicine and Dentistry. He currently serves as Director of the Clinical Research Center -the Clinical and Translational Sciences Institute (CTSI) and as Clinical Director of the Center for Medical Technology and Innovation at the University of Rochester. He is a practicing cardiologist who has developed the CytoComm™ technology through years of work with patients. As a specialist in heart rhythm disorders, Dr. Rosero treats patients using a wide range of therapeutic options, including radiofrequency ablation of abnormal rhythms, implantation of electronic medical devices such as pacemakers, defibrilllators (ICD's), and cardiac resynchronization therapy devices. He is an experienced clinical investigator and has actively participated in several large multicenter trials studying the role of medical devices in treating patients with heart failure and life threatening arrhythmias. As the site principal investigator for the early evaluation of a novel implantable left atrial pressure monitoring system at the University of Rochester, Dr. Rosero's team was the first in the nation to implant the St. Jude Heart Pod device. His research interests include living cell embedded biosensors, hereditary arrhythmias, and futuristic medical device technologies that support personalization of medical care.

Matthew Colpoys

COO

Mr. Colpoys is an experienced executive in the biopharma/medtech industry. Since leaving Genentech in 1995, he has been involved in the startup and structuring of more than a dozen companies as either an active member of senior management or in his role as a consultant via his activities as President of Galileo Consulting, Inc. His 30 years of experience across a broad range of operational activities makes him a valued associate at Efferent Labs. Mr. Colpoys assist's in the formulation of strategy and communication with potential collaborators and licensees.

Jack Greco

CFO

Mr. Greco, an entrepreneur and venture advisor and founder of Cupule Ventures, provides venture development and support to early stage Biotech, Life Science, Material Science and Technology companies, concentrated across Upstate New York. Taking a hands-on role, Greco manages executive, financial and operational functions, as his efforts have centered in formation, management, fundraising and growing commercial operations. Instrumental in the launching and growth of 20+ start-ups, primarily of higher technology or advance manufacturing pedigrees, Greco managed the investment efforts of 10+ successful private placements and managed several acquisitions, domestic and international.

Previous to founding Cupule, Greco was a Venture Associate on two funds with Trillium Group, LLC, in Rochester, NY, eclipsing $135M in investments and has deep entrepreneurial roots of his own, starting his first company in 2003. He has an M.B.A. from the Simon School of Business Administration and a B.A. in Economics from the University of Rochester.

Brian McIlroy, PhD

Vice President Operations

Dr. McIlroy began his career at the National Medical Laser Center in London England that is part of the University of London. While there he was responsible for all the laser treatments and maintenance of the clinical and non-clinical laser systems. While working at NMLC he also carried out a PhD in the specialized area of Photodynamic Therapy Dosimetry (PDT. Dr,. McIlroy then moved on to work with the research group in the area of PDT at the Ontario Caner Institute in Toronto. He was then recruited to North Carolina in 2000 as Director of Science, to set up the PDT program at the Leo Jenkins Cancer Center in Greenville North Carolina. While there he was responsible for setting up the infrastructure, the clinical program as well as a scientific program within the department of Physics.

Dr. McIlroy moved to GE Global Research in Albany NY as the head of a new program in Bioinstumentation. Over the course of his tenure at GE Research he held many roles finishing as a global technical leader responsible for all advanced technology across 4 GE Healthcare business units, with 75+ people and a budget responsibility of $40M.

He was then promoted into what became GE Ventures as the Healthcare leader responsible for monetizing the technology and knowhow across GE Healthcare. Later he was promoted to Managing Director for Alliance management for North and South America with the entire GE portfolio of 95,000 articles of IP from all business units.

Overall Dr. McIlroy has over 20 years experience in all aspects of medical device development together with management of clinical trials ranging from preclinical through phase III FDA controlled global trials.

Kristian Pettengill

Vice President Sales and Marketing

As a seasoned sales executive, Kristian brings over 25 years of sales leadership and turnaround experience to Efferent Labs. His experience includes executive sales and marketing experience roles at several Pharma and medical device companies.

Krishna Gnanasambandam, PhD

Chief Scientist

Dr. Gnanasambandam is responsible for the research labs at Efferent. He is a former assistant professor and research scientist at the University at Buffalo. His experience includes scientific design and experiment execution, result interpretation and reporting

Dr. Gnanasambandam is a broadly-trained biologist with extensive experience working on neurodegenerative disorders and ion channel biology. Expertise acquired from working in the above-mentioned areas include molecular biology/genetics, electrophysiology and imaging (fluorescence, calcium and SIM), cell culture of primary neuronal cells (neurons and glia) and cell-lines, adeno/retroviral gene manipulation, animal models (Drosophila and mice) and microfluidics devices.

He is proficient at Visual basic, Python and C++. Adept at using regression and modeling kinetics in the biological sciences, especially in the context of ion channels. I also have experience with analog circuit design and computer-aided design.